Obesity-associated prostate cancer (PCa) remains controversial, although most studies rely on body mass index evaluation, which is an indirect measure of fatness. Studies using body fat measurement and disease stratification according to PCa stage found stronger associations between obesity and PCa. Leptin is a pleiotrophic hormone mainly synthesized by adipocytes that acts in peripheral organs such as the prostate. This article reviews obesity-associated leptin's pathophysiological role in PCa progression. PCa development results from some known risk factors. Currently, there is enough evidence suggesting that leptin is an additional factor involved in advanced PCa occurrence, and obesity association with high-grade disease. Life-long exposure to genetic and/or environmental susceptibility factors that predispose to obesity and higher leptin levels may increase the risk for advanced PCa.
Introduction
The prevalence of obesity in developed countries markedly increased over the last decades to an extent considered epidemic. 1 The obesity-associated increased risk for cancer is well documented in many model systems, 2 including those for prostate cancer (PCa). The rising prevalence of overweight and obesity in developed countries probably will be in the near future responsible by a significant proportion of cancers. Furthermore, the diagnosis is difficult because lower levels of prostate-specific antigen (PSA) in obese and overweight men could mask consequential PCa. 3 There has been an increasing interest on the study of cellular and molecular mechanism of cancer by energy restriction models. 4 Berrigan et al. 5 and Mai et al. 6 observed that the relationship between energetic balance and cancer development could be explained to a great extent by caloric restriction, as mediated through leptin.
Leptin is a hormone with a central role in obesity and is secreted principally by adipocytes, which contributes to the concept of adipocyte and adipose tissue as an endocrine cell and an endocrine organ, respectively. Recent reviews state that leptin is involved in increased susceptibility for cancer, particularly of the breast and prostate. [7] [8] [9] [10] In this article we review the leptin pathway from the obesity state to PCa susceptibility and progression to advanced disease.
Obesity and PCa
The OECD Health Data 2004 11 shows that in Europe (19 countries with repeated measures of BMI since 1980 until 2003), the obesity prevalence is increasing. Among the USA population, there were about 20% of obese individuals. 12 Asian countries, historically nonobese populations, also had pronounced increase in obesity prevalence during the last years. 13 Concomitantly, over the last years PCa incidence has also increased. In the United States, PCa incidence annual percent change increased 2.7 in the time period of 1973-1988, 16.2 in 1988-1992 , and À11.7 in 1992-1995.
14 It seems that PCa incidence follows obesity incidence (Figure 1) , except for the years 1992-1995 when after a peak of PCa incidence attributable to implementation of PSA screening, there was an expected decrease to normal detection rate.
There are inconclusive results concerning PCa association with dietary fat and calories intake 17 and with obesity and overweight. 18 Nevertheless, there is considerable amount of evidence that favors the association of obesity to higher-grade or -stage prostatic tumors.
The aforementioned inconsistencies among studies may be due to the methods used for assessing obesity. There are contradictory results from several studies using body mass index (BMI) to evaluate adiposity. [24] [25] [26] [27] [28] [29] However, studies using abdominal adiposity measurement, either by waist-to-hip ratio 30 or CT scan, 31 found an increased risk for PCa.
An explanation for such conflicting results might be the failure to distinguish peripheral from central fat. Epidemiological reports of obesity have been based upon anthropometrical measures such as BMI, which are, particularly in men bearing greater muscle mass, inadequate estimates of adiposity. Among the elderly, the age group most affected by PCa, BMI could be a less valid indicator of adiposity, because they tend to have a shift of fat from peripheral to central sites with a concomitant waist-to-hip ratio at the same level of BMI. 32 Actually, there is agreement to expand the adipocyte role beyond fat storage, because of its crucial regulatory actions to whole body physiology. Nevertheless, the over storage of fat may contribute to the pathogeny of obesityrelated diseases. 33 In fact, adipocytes secrete several cytokines known to contribute to an obesity-associated inflammatory state. 34, 35 This chronic inflammatory state may predispose to cancer etiopathogenesis, through adipokines roles that help to explain the molecular basis of obesity-associated PCa.
Several proteins secreted by adipocytes (leptin, TNFa, IL-6, TGFb, IGF-I) are important mediators in PCa development and/or progression. [36] [37] [38] [39] [40] Here we describe the leptin pathway.
Pathophysiology of obesity: leptin's role
Research on obesity pathophysiology has been recently intensified, largely because of the discovery of leptin gene. 41 Leptin is a 16-kDa protein, whose gene was previously cloned and sequenced. 41 Its main roles are regulation of energy balance and mediation of the adaptation to fasting. Plasma leptin levels correlate with fat stores 42 and the volume and number of adipocytes. 43, 44 Although leptin decreases body weight and fat content, hiperleptinemia found in obese subjects probably reflects leptin resistance 45 and fat depots.
Serum leptin levels seem to be dependent on body fat distribution. Some reports suggest it is better correlated with subcutaneous rather than visceral fat. 46, 47 However, a study conducted in monozygous twins discordant for obesity, demonstrated an association of the visceral fat area with leptin levels in men. 48 Furthermore, Tong et al. 49 found that circulating leptin level predicted visceral fat accumulation at 5 and 10 years follow-up. Cumulatively, omental adipose tissue expresses more leptin with aging, 50 while PCa risk increases with age. These results suggest that age and type of obesity can influence leptin concentration in serum.
Environmental factors such as diet are additional key regulators of leptin secretion by adipocytes. A westernalized saturated fat-rich diet accounts for significant increases in plasma leptin. 51, 52 The leptin gene (LEP) has several polymorphisms (SNPs) at the 5 0 flanking region. These polymorphisms might be responsible for functional abnormalities in leptin, and one (À2548 G/A) was shown to be associated with an overexpression of leptin mRNA 53 and higher serum levels. 53, 54 Positional cloning of the leptin receptors (LEPR) confirmed their location in the hypothalamus and choroids plexus, areas known to regulate feeding behavior, 55 as well as in several peripheral tissues. 56 The presence of LEPR in prostatic tissue and prostate tumors has already been demonstrated, 57, 58 suggesting a plausible biological role for leptin in this gland (Figure 2 ). In fact, leptin seems to have a stimulatory role in prostate growth during puberty. 59 Whereas genetic characteristics predispose to lifelong exposure to higher leptin production in carriers of the overexpressing functional variant of the LEP gene (À2548 G/A), studies on adiposity usually reflect a onemoment evaluation, when the cumulative effect of fat content (all-life exposure) may be relevant in cancer development.
Early since fetal life, we are exposed to hormones and environmental factors that will influence health and obesity throughout life. 60 Leptin levels in cord blood derived from placenta and fetal tissues 61 correlate with Obesity and prostate cancer R Ribeiro et al body mass and fat mass of the neonate 62 and with fetal fat depots. 63 Furthermore, autopsy studies found that microscopic foci of PCa and high-grade prostatic intraepithelial neoplasia occur earlier than clinical findings 64 and many could never been discovered in a screening program. 64, 65 We hypothesize that all-life exposure to obesity-associated genetic and environmental factors is relevant for PCa development. The shift towards clinical manifestations may depend upon the cumulative effect of time exposed to obesity, saturated fat intake and genetic susceptibility.
Leptin and PCa
Measurement of serum leptin in case-control studies with PCa patients have been used to demonstrate leptin involvement in PCa. The risk for PCa in individuals with higher levels of leptin has not been demonstrated. 66, 67 However, it was found that higher leptin levels were linked to tumor progression and advanced disease. 38, 68 We conclude from these investigations that leptin may be predominantly relevant in PCa progression. Studies on this issue should evaluate the grade and stage of PCa patients.
In vitro studies on PCa cell lines showed that leptin promotes proliferation of androgen-independent PCa 69, 70 and induces cell migration and the expression of growth factors in PCa cells. 71 These results suggest that studies undertaken to ascertain leptin and/or obesity association to PCa should differentiate patients according to androgen resistance.
Molecular genetics studies on LEP and LEPR polymorphisms showed higher risk (OR ¼ 4.67) for advanced disease in a functional variant in LEP gene. 72 In the LEPR variant there was lack of association to PCa. 73 The frequencies of genotype distribution found for the LEP variant in normal controls from several countries, evidence a positive correlation of the risk genotype with PCa incidence in those populations, in the context of a gene/environmental model. 72 Leptin interaction with several hormones and/or growth factors that are involved in PCa is an additional pathway showing leptin indirect action in prostatic cells.
Tumor and host produced proinflammatory cytokines (IL-6, IL-1, TNFa) upregulate the OB gene in adipose tissue, 74 while leptin induces IL-6 and IGF-I production. This self-perpetuating loop allows tumor growth, involving leptin and other adipocytic molecules, contributing for tumor progression to advanced disease (Figure 3) .
These lines of evidence from epidemiological, cell lines and genetics suggest that leptin has an important role in the development of advanced PCa.
There is evidence supporting this additional mechanism of PCa development, which relies on LEP gene interaction with life events, namely body fatness and saturated fat intake. This gene-environment relation is further supported by epidemiological data on geographic PCa incidence, dietary habits and genetic background. We recently identified the LEP À2548 AA as a risk genotype for PCa; however, the frequency of this homozygous in normal controls varies among populations (Table 1) . Apparently, there is incongruence according to the risk genotype frequency in Japan (60.8%) and the incidence of PCa in this country (11.1 ASR_W), 77 one of the lowest in the world. However, an earlier study by Wittemore et al. 78 showed that JapaneseAmericans had even greater risk for PCa than AfricanAmerican or Caucasian-American populations and that it was associated with saturated fat intake. Accordingly, Shibata et al. 79 observed higher incidence of PCa in Japanese-American compared to native Japanese. The association of genetic predisposition with lifestyle reflect the interaction of genes with environmental issues in PCa development.
Current hormonal therapy for PCa includes the use of antiandrogens, LHRH agonists and antagonists or combined androgen blockade. 80 The purpose of these pharmacological approaches is to lower androgen serum levels, which will induce a hormonal deregulation leading to leptin overexpression. 9 The unbalanced serum Obesity and prostate cancer R Ribeiro et al increase in leptin and decrease in androgens may facilitate androgen-independent cell growth, while downregulating androgen-dependent cells. The association of factors contributing to higher levels of leptin, for example, obesity, dietetic habits, leptin resistance, genetic variant in LEP, will increase further leptin production by adipocytes and gives ground for progression to androgen-independent PCa.
Thus, hormonal therapeutic intervention in advanced PCa or androgen-independent PCa should take into account individual genetic, hormonal and anthropometrical profile. Blocking peripheral leptin action, at either LEPR or intracellular pathways, without interfering with its physiological functions, will be a serious challenge to pharmacological sciences.
Conclusions
PCa is a multifactorial disease with some well-established mechanisms. Leptin's involvement in PCa development is an interesting emerging field of investigation.
Leptin is a key mediator of obesity and is involved in PCa progression. Its molecular, endocrinologic and genetic features may concur, directly or indirectly, to PCa development.
Results from epidemiological studies may be biased by measurement error, by not considering all-life exposure to obesity or by not adjusting for true body fat content. Most studies evaluating obesity in PCa patients use indirect methods to measure fat mass content or particularly visceral adiposity. These studies may contribute to conflicting results. Another source of confounding may arise from the lack of stratification of patients by PCa grade or androgen-sensibility. Stratification could help find groups of patients with an obesityassociated risk.
Further studies, using disease stratification and adequate methods to evaluate fat content, are required to clarify obesity role in PCa carcinogenesis and/or progression. Longitudinal studies evaluating all-life exposure to obesity/diet and leptin's genetic/metabolic roles will help to elucidate the effect of such conditioning factors in PCa.
